Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
131I-apamistamab · 1 trial · 11 indications
| Name | Type | Description |
|---|---|---|
| 131I-apamistamab | DRUG | Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose. |
| Fludarabine | DRUG | Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2. |
| Cyclophosphamide | DRUG | Cyclophosphamide |
| Total Body Irradiation (TBI) | RADIATION | TBI, 200 cGy on Day -1 prior to HSCT. |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | BIOLOGICAL | Unmodified, G-CSF-mobilized donor stem cells infused on Day 0. |
131I-apamistamab is an investigational radioimmunotherapy being studied for use in acute leukemia, specifically as conditioning for allogeneic transplant in patients with relapse or refractory acute myeloid leukemia (AML). It is being evaluated in a Phase 2/Phase 3 clinical trial.
131I-apamistamab is a radiolabeled antibody that delivers iodine-131 radiation directly to leukemia cells. It is designed to target and irradiate malignant cells as part of a conditioning regimen before allogeneic stem cell transplant, potentially reducing disease burden while preparing the patient for transplantation.
131I-apamistamab is being developed by Actinium Pharmaceuticals, Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol ATNM. The company is conducting clinical research to evaluate the drug's safety and efficacy in acute leukemia.
131I-apamistamab is currently in Phase 2/Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trial is designed to assess its use as conditioning therapy for allogeneic transplant in patients with relapse or refractory AML.
131I-apamistamab is being studied in a single clinical trial registered as NCT07157514, titled 'Radioimmunotherapy Conditioning With 131I-Apamistamab for Allogeneic Transplant in Relapse/Refractory AML.' This Phase 2/Phase 3 trial is not yet recruiting and aims to enroll approximately 306 patients with acute leukemia, including AML.
131I-apamistamab is a radiolabeled form of the antibody apamistamab, where iodine-131 is attached to the antibody. The drug is referred to as 131I-apamistamab in clinical trials, and the name reflects the radioactive isotope component of the investigational therapy.